1.06
+0.03(+2.91%)
Currency In USD
| Previous Close | 1.03 |
| Open | 1.05 |
| Day High | 1.08 |
| Day Low | 1.03 |
| 52-Week High | 2.24 |
| 52-Week Low | 0.77 |
| Volume | 366,325 |
| Average Volume | 913,973 |
| Market Cap | 88.75M |
| PE | -3.12 |
| EPS | -0.34 |
| Moving Average 50 Days | 1.1 |
| Moving Average 200 Days | 1.19 |
| Change | 0.03 |
If you invested $1000 in Cardiol Therapeutics Inc. (CRDL) since IPO date, it would be worth $283.3 as of October 20, 2025 at a share price of $1.06. Whereas If you bought $1000 worth of Cardiol Therapeutics Inc. (CRDL) shares 5 years ago, it would be worth $404.58 as of October 20, 2025 at a share price of $1.06.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cardiol Therapeutics Secures US$11 Million Financing and Extends Cash Runway into Q3 2027
Newsfile
Oct 17, 2025 8:34 PM GMT
MAVERIC Phase III pivotal trial of orphan drug candidate CardiolRx™ in recurrent pericarditis is fully funded through to a planned New Drug Application submission with the FDA.New data from the ARCHER trial, highlighting the magnitude of reduction in
Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 45th Annual Growth Conference
Newsfile
Aug 11, 2025 11:27 AM GMT
Toronto, Ontario--(Newsfile Corp. - August 11, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for t
Cardiol Therapeutics Announces Topline Results from the Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis
Newsfile
Aug 06, 2025 11:27 AM GMT
Change in the primary endpoint of left ventricular (LV) extracellular volume (ECV) showed a notable improvement (p = 0.0538) favouring CardiolRx™ over placebo.Reduction in ECV was associated with improvements across multiple pre-specified cardiac mag